Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02232308 · ClinicalTrials.gov registry record · Phase 1
Modulation of Heme Oxygenase 1 by Nizatidine and Lisinopril in Healthy Subjects
A Phase 1 study of Gastroparesis, sponsored by Adil Bharucha.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 2
- Study locations
NCT02232308: Completed Phase 1 study of Gastroparesis, sponsored by Adil Bharucha.
NCT02232308 is a Phase 1 study of Gastroparesis that has completed, run by Adil Bharucha. The registered enrollment target is 24 participants, below the 302-participant average among 44 other Gastroparesis trials with a reported enrollment target (92% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02232308, a Phase 1 study of Gastroparesis, has completed, sponsored by Adil Bharucha.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 2
- Study locations
Study Summary
To assess if oral nizatidine or lisinopril alone and in combination will increase heme oxygenase 1 (HO-1) protein concentration and activity compared to placebo in healthy subjects.
Primary Outcome
Heme oxygenase (HO-1) degrades heme and protects against oxidative stress. HO-1 concentration was measured by a blood test; the units are ng/ml.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Lisinopril
- DRUG Nizatidine
Study Locations (2)
Minnesota
- Mayo Clinic in Rochester - Rochester
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2014-07 |
| Est. Completion | 2014-09 |
| Phase | Phase 1 |
What the finished NCT02232308 record still lists
NCT02232308 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 302-participant average among 44 other Gastroparesis trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Gastroparesis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02232308 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT02232308 about?
NCT02232308 is a clinical study titled "Modulation of Heme Oxygenase 1 by Nizatidine and Lisinopril in Healthy Subjects". To assess if oral nizatidine or lisinopril alone and in combination will increase heme oxygenase 1 (HO-1) protein concentration and activity compared to placebo in healthy subjects.
What is the current status of trial NCT02232308?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2014-07. Estimated completion is 2014-09.
What conditions does trial NCT02232308 study?
This clinical trial studies the following conditions: Gastroparesis.
What interventions are being tested in trial NCT02232308?
The interventions under investigation include: Placebo (DRUG), Lisinopril (DRUG), Nizatidine (DRUG).
Who is sponsoring clinical trial NCT02232308?
This trial is sponsored by Adil Bharucha, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02232308 being conducted?
This trial has 2 study locations across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastroparesis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02232308's enrollment target sits among peer trials
24 32nd of 44 higher than 13 of 44 other Gastroparesis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastroparesis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TENS in Scleroderma
RECRUITING · Phase 1
-
Study to Assess Pharmacodynamics of RM-131 in Patients With Diabetic Gastroparesis
COMPLETED · Phase 1
-
Safety and Pharmacokinetic Study of C13-URA in Healthy Volunteers
COMPLETED · Phase 1
-
Gastroparesis Registry 4
RECRUITING
-
The Use of Body Surface Gastric Mapping in Assessing the Clinical Success of G-POEM
RECRUITING · NA
-
Study of Gastric Motility in Eosinophilic Gastritis
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia